| Aims and background: Long noncoding RNAs(LncRNAs),a new-found class of noncoding RNA,have been demonstrated playing crucial roles in the occurrence and development of gastric cancer.However,the diagnostic values of most LncRNAs are largely unknown.The purpose of this study is to investigate whether LncRNA-RPLP0P2(ribosomal protein,large,P0 pseudogene 2)can be served as a biomarker for gastric cancer.Methods: We first detected RPLP0P2 level in gastric cancer tissues and adjacent paired normal tissues using quantitative real-time reverse transcription-polymerase chain reaction(qRTPCR).Then,we further explored the relationships between RPLP0P2 expression levels and clinicopathological factors of patients with gastric cancer.Third,we used small interfering RNA to observe RPLP0P2’s role in cell proliferation.Fourth,We compared plasma RPLP0P2 levels between healthy controls with gastric cancer patients before and after surgery.Fifth,using the ROC curve to evaluate the value of plasma RPLP0P2 in the diagnosis of gastric cancer.Sixth,we analyzed the relationship between the expression of RPLP0P2 and the survival time in gastric cancer tissues by using survival curve.Results:(1)RPLP0P2 expression was unregulated in gastric cancer tissues comparing with adjacent paired normal tissues.More important,its levels in cancer tissues were positively associated with Borrmann type(p = 0.049),invasion(p = 0.024)and Perineural invasion(p = 0.027).By knockdown of RPLP0P2 expression,cell proliferation was significantly suppressed.(2)There was no significant difference in plasma RPLP0P2 level between patients with gastric mucosal hyperplasia and healthy controls(3)The level of plasma RPLP0P2 in patients with gastric cancer was significantly lower than that before operation(4)Serum RPLP0P2 as a marker of gastric cancer,it’s sensitivity is 60.1% and the specificity is 66.3%,respectively.Conclusions: RPLP0P2,as a new LncRNA,may be a potential tumor marker and a therapeutic target for gastric cancer. |
PDF Full Text Request